BSE Live
Dec 04, 16:01Prev. Close
935.90
Open Price
936.55
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 04, 15:59Prev. Close
934.95
Open Price
938.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
935.75 (283)
| Key Financial Ratios of Zydus Lifesciences (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 44.97 | 38.14 | 19.30 | 43.83 | 20.84 | |
| Diluted EPS (Rs.) | 44.97 | 38.14 | 19.30 | 43.83 | 20.84 | |
| Cash EPS (Rs.) | 54.98 | 45.91 | 26.88 | 51.61 | 27.41 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 238.10 | 219.70 | 194.55 | 186.07 | 145.80 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 238.10 | 219.70 | 194.55 | 186.07 | 145.80 | |
| Revenue from Operations/Share (Rs.) | 231.03 | 194.31 | 170.33 | 149.07 | 140.66 | |
| PBDIT/Share (Rs.) | 72.84 | 56.35 | 39.99 | 34.82 | 33.52 | |
| PBIT/Share (Rs.) | 63.74 | 48.75 | 32.84 | 27.86 | 26.98 | |
| PBT/Share (Rs.) | 59.91 | 47.80 | 25.59 | 27.72 | 23.43 | |
| Net Profit/Share (Rs.) | 45.87 | 38.31 | 19.74 | 44.65 | 20.88 | |
| NP After MI And SOA / Share (Rs.) | 44.99 | 38.36 | 19.37 | 43.82 | 20.84 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 31.52 | 28.99 | 23.47 | 23.35 | 23.83 | |
| PBIT Margin (%) | 27.58 | 25.08 | 19.28 | 18.68 | 19.18 | |
| PBT Margin (%) | 25.93 | 24.60 | 15.02 | 18.59 | 16.65 | |
| Net Profit Margin (%) | 19.85 | 19.71 | 11.58 | 29.95 | 14.84 | |
| NP After MI And SOA Margin (%) | 19.47 | 19.74 | 11.37 | 29.39 | 14.81 | |
| Return on Networth/Equity (%) | 18.89 | 19.46 | 11.19 | 26.39 | 16.42 | |
| Return on Capital Employed (%) | 22.77 | 20.48 | 16.43 | 14.29 | 17.24 | |
| Return on Assets (%) | 12.16 | 13.18 | 7.61 | 16.14 | 8.93 | |
| Total Debt/Equity (X) | 0.13 | 0.04 | 0.07 | 0.25 | 0.35 | |
| Asset Turnover Ratio (%) | 0.70 | 0.71 | 0.64 | 0.38 | 0.37 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.89 | 2.15 | 1.81 | 1.56 | 1.11 | |
| Quick Ratio (X) | 1.45 | 1.51 | 1.19 | 1.09 | 0.70 | |
| Inventory Turnover Ratio (X) | 6.29 | 1.34 | 1.16 | 1.02 | 1.03 | |
| Dividend Payout Ratio (NP) (%) | 6.67 | 16.08 | 13.59 | 8.29 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 5.54 | 13.42 | 9.93 | 7.15 | 0.00 | |
| Earnings Retention Ratio (%) | 93.33 | 83.92 | 86.41 | 91.71 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 94.46 | 86.58 | 90.07 | 92.85 | 0.00 | |
| Coverage Ratios | ||||||
| Interest Coverage Ratios (%) | 44.17 | 69.81 | 31.15 | 28.07 | 21.62 | |
| Interest Coverage Ratios (Post Tax) (%) | 44.17 | 69.81 | 31.15 | 28.07 | 21.62 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 91,719.42 | 103,063.75 | 52,502.40 | 40,850.18 | 50,775.54 | |
| EV/Net Operating Revenue (X) | 3.95 | 5.27 | 3.05 | 2.68 | 3.53 | |
| EV/EBITDA (X) | 12.52 | 18.18 | 12.97 | 11.46 | 14.79 | |
| MarketCap/Net Operating Revenue (X) | 3.83 | 5.17 | 2.89 | 2.34 | 3.13 | |
| Retention Ratios (%) | 93.32 | 83.91 | 86.40 | 91.70 | 0.00 | |
| Price/BV (X) | 3.72 | 5.10 | 2.84 | 2.10 | 3.47 | |
| Price/Net Operating Revenue | 3.83 | 5.17 | 2.89 | 2.34 | 3.13 | |
| Earnings Yield | 0.05 | 0.04 | 0.04 | 0.13 | 0.05 |
28.11.2025
Zydus Lifesciences shares gain on tentative USFDA approval for Empagliflozin, Linagliptin tablets
28.11.2025
26.11.2025
14.11.2025
12.11.2025
Zydus Life Standalone September 2025 Net Sales at Rs 2,871.20 crore, up 9.56% Y-o-Y
07.11.2025
Zydus Life Consolidated September 2025 Net Sales at Rs 6,123.20 crore, up 16.92% Y-o-Y
10.09.2025
Zydus Life Standalone June 2025 Net Sales at Rs 2,588.30 crore, down 37.78% Y-o-Y
24.06.2025
Zydus Life Consolidated March 2025 Net Sales at Rs 6,527.90 crore, up 17.96% Y-o-Y
12.07.2023
Zydus Lifescience Q1 PAT seen up 58.6% YoY to Rs 839.1 cr: Nirmal Bang
08.07.2022
Zydus Lifesciences Q1 PAT may dip 10.6% YoY to Rs 505.2 cr: Prabhudas Lilladher
13.01.2022
Cadila Healthcare Q3 PAT seen up 3.2% YoY to Rs 544 cr: Prabhudas Lilladher
06.10.2021
Cadila Healthcare Q2 PAT seen up 19% YoY to Rs 563.3 cr: Prabhudas Lilladher